Equity Profile

AMRX

Amneal Pharmaceuticals, Inc.

Health CarePharmaceuticals$5.9B

Aug4Tue

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Amneal Pharmaceuticals, Inc. (AMRX) is a healthcare company that develops and manufactures generic and specialty pharmaceuticals....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

$0.24

Revenue

Revenue growth is essential for assessing the company's market performance and ability to generate sales.

$811M

Wall Street expectations, options signals, track record, and call prep available with Pro.

AMRX Q2-2026 Earnings Preview

Context

Company Snapshot

Amneal Pharmaceuticals, Inc. (AMRX) is a healthcare company that develops and manufactures generic and specialty pharmaceuticals. With a market cap of $6 billion, it plays a significant role in providing affordable medications, especially as healthcare costs continue to rise.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+34.60%

Avg Stock Reaction

-0.24%

Last Quarter Recap

In Q1-2026, Amneal reported an EPS of $0.27, exceeding expectations by 8%. However, the stock price fell by 1.54% the following day, indicating mixed investor sentiment.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect Amneal to report an EPS of $0.24 and revenue of $811 million for Q2-2026. The market is closely watching these figures as they could signal future growth.

Bull Case

If Amneal beats EPS expectations and demonstrates strong revenue growth, it could indicate robust demand for its products, potentially boosting investor confidence.

Bear Case

Conversely, if the company fails to meet expectations or provides weak guidance, it may raise concerns about its competitive position and profitability.

Key Metrics to Watch

Earnings Per Share (EPS)

$0.24

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

Revenue

$811M

Revenue growth is essential for assessing the company's market performance and ability to generate sales.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Amneal's EPS exceed the consensus estimate of $0.24?

A beat on EPS could indicate strong operational performance and boost investor confidence.

What guidance will management provide regarding future revenue growth?

Future revenue guidance will be crucial for assessing the company's growth trajectory and market position.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may be underestimating Amneal's ability to leverage its recent product launches, which could drive higher-than-expected revenue growth.

Supporting Evidence

The company has consistently beaten EPS estimates in recent quarters, indicating strong operational execution.

Options pricing suggests a significant move, which may reflect investor uncertainty about the company's growth prospects.

Key Risk

If Amneal's revenue growth exceeds $820 million, it could challenge the current market expectations.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will hinge on whether Amneal can maintain its growth momentum and meet or exceed market expectations.

Bull Confirmed If

An EPS of $0.26 or higher would confirm the bull case, indicating strong operational performance.

Bear Confirmed If

An EPS below $0.22 would confirm the bear case, raising concerns about profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±22.47%

Historical Avg

±2.7%

Pricing rich

The options market is pricing in a significant move, suggesting that investors anticipate volatility around the earnings report.

Options are pricing ±22.5% while AMRX has averaged ±2.7% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.8%

30d HV

36.1%

Calls (400)P/C Ratio: 1.16Puts (0)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Amneal beats expectations, history suggests the stock could rise, confirming strong demand and operational efficiency.

In-Line / Cautious

If results are in line with expectations, the stock may react cautiously as investors await further guidance.

Miss

Should the company miss estimates, history suggests a potential decline in stock price, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches and their expected impact on revenue.
2Management's commentary on market conditions and competitive landscape.
3Insights into cost management strategies and their effect on margins.
4Any changes in guidance for the remainder of the fiscal year.
5Details on customer demand trends and inventory levels.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Amneal Pharmaceuticals, Inc. (AMRX) is a healthcare company that develops and manufactures generic and specialty pharmaceuticals....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

$0.24

Revenue

Revenue growth is essential for assessing the company's market performance and ability to generate sales.

$811M

Wall Street expectations, options signals, track record, and call prep available with Pro.

AMRX Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+34.60%

Avg Stock Reaction

-0.24%

Last Quarter Recap

In Q1-2026, Amneal reported an EPS of $0.27, exceeding expectations by 8%. However, the stock price fell by 1.54% the following day, indicating mixed investor sentiment.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect Amneal to report an EPS of $0.24 and revenue of $811 million for Q2-2026. The market is closely watching these figures as they could signal future growth.

Bull Case

If Amneal beats EPS expectations and demonstrates strong revenue growth, it could indicate robust demand for its products, potentially boosting investor confidence.

Bear Case

Conversely, if the company fails to meet expectations or provides weak guidance, it may raise concerns about its competitive position and profitability.

Key Metrics to Watch

Earnings Per Share (EPS)

$0.24

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

Revenue

$811M

Revenue growth is essential for assessing the company's market performance and ability to generate sales.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Amneal's EPS exceed the consensus estimate of $0.24?

A beat on EPS could indicate strong operational performance and boost investor confidence.

What guidance will management provide regarding future revenue growth?

Future revenue guidance will be crucial for assessing the company's growth trajectory and market position.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may be underestimating Amneal's ability to leverage its recent product launches, which could drive higher-than-expected revenue growth.

Supporting Evidence

The company has consistently beaten EPS estimates in recent quarters, indicating strong operational execution.

Options pricing suggests a significant move, which may reflect investor uncertainty about the company's growth prospects.

Key Risk

If Amneal's revenue growth exceeds $820 million, it could challenge the current market expectations.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will hinge on whether Amneal can maintain its growth momentum and meet or exceed market expectations.

Bull Confirmed If

An EPS of $0.26 or higher would confirm the bull case, indicating strong operational performance.

Bear Confirmed If

An EPS below $0.22 would confirm the bear case, raising concerns about profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±22.47%

Historical Avg

±2.7%

Pricing rich

The options market is pricing in a significant move, suggesting that investors anticipate volatility around the earnings report.

Options are pricing ±22.5% while AMRX has averaged ±2.7% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.8%

30d HV

36.1%

Calls (400)P/C Ratio: 1.16Puts (0)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Amneal beats expectations, history suggests the stock could rise, confirming strong demand and operational efficiency.

In-Line / Cautious

If results are in line with expectations, the stock may react cautiously as investors await further guidance.

Miss

Should the company miss estimates, history suggests a potential decline in stock price, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches and their expected impact on revenue.
2Management's commentary on market conditions and competitive landscape.
3Insights into cost management strategies and their effect on margins.
4Any changes in guidance for the remainder of the fiscal year.
5Details on customer demand trends and inventory levels.